Central People's Hospital of Zhanjiang
Central People's Hospital of Zhanjiang
Explore linked clinical trials.7 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 2 | 2026-05-04 | NCT05491811 | |
| Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients | B-cell acute lymphoblastic leukemia, B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Tumor Virus Infections, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, neoplasm, viral infectious disease | Recruiting | Not applicable | 2026-03-10 | NCT06343090 | |
| CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-03-10 | NCT06316856 | |
| A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 / Phase 2 | 2025-11-26 | NCT07070323 | |
| Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, T-cell acute lymphoblastic leukemia, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 / Phase 2 | 2025-11-26 | NCT06316427 | |
| Interleukin-6 Receptor Inhibition for Symptomatic Intracranial Atherosclerosis | Arterial Occlusive Diseases, Disease Attributes, Infarction, Intracranial Atherosclerosis, Necrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, arteriosclerosis disorder, atherosclerosis, brain disorder, brain infarction, brain ischemia, cardiovascular disorder, central nervous system disorder, cerebral infarction, cerebrovascular disorder, intracranial arterial disease, intracranial arteriosclerosis, ischemic disease, ischemic stroke, nervous system disorder, stroke disorder, vascular disorder | Not yet recruiting | Phase 3 | 2025-07-28 | NCT06447701 | |
| CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Not yet recruiting | Phase 4 | 2025-01-08 | NCT06763666 |